Geographic Variation in Diagnostic Performance of Amsel Criteria and Nugent Score for Vaginal Dysbiosis Defined by 16S rRNA Gene Sequencing
- 11 August 2026
- journal article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (4) , 609-619
Abstract
Background: Vaginal dysbiosis characterized by low abundance of vaginal lactobacilli and increased bacterial community diversity, is implicated in multiple adverse health outcomes and is an emerging target for preventive interventions, including live biotherapeutic products. The most common clinical presentation of vaginal dysbiosis is bacterial vaginosis (BV), but at least half of people are asymptomatic. Methods: We compared identification of BV by Nugent score and Amsel criteria for screening specimens from a Phase 1b randomized trial of a live biotherapeutic product conducted at 2 sites (CAPRISA, South Africa; MGH, USA), as well as a single follow-up visit from enrolled participants. Using 16S rRNA gene sequencing-based categorization of community state type (CST) as the reference and multinomial mixed-effects logistic models, we evaluated the association of Amsel BV and Nugent BV with CST IV (including subtypes IV-A and IV-B) and tested for site-specific effects. Results: Amsel BV was significantly associated with CST IV-A and IV-B; however, the strength of association was significantly diminished at CAPRISA compared with MGH, pointing to site-specific assessment differences or underlying biological variation. Nugent BV yielded stronger associations with CST IV-A, and IV-B and showed no evidence of a site-specific interaction, indicating consistent performance across sites. Conclusions: These findings indicate that diagnostic performance for vaginal dysbiosis varies by framework: Amsel criteria are more susceptible to geographical site effects, whereas Nugent score demonstrates stronger and more site-agnostic associations. For clinical studies targeting vaginal dysbiosis, Nugent scoring and/or sequencing-based approaches should be prioritized for vaginal dysbiosis endpoint definition and stratification.Keywords
Funding Information
- Bill and Melinda Gates Foundation (INV-019055)
- Bill and Melinda Gates Foundation (INV-037901)
- Bill and Melinda Gates Foundation (INV-037902)
This publication has 40 references indexed in Scilit:
- VIBRANT: A phase 1 randomized trial of multi-strain vaginal L. crispatus live biotherapeutic products in people with bacterial vaginosisCell Host & Microbe, 2026
- Randomized trial of multi-strain Lactobacillus crispatus vaginal live biotherapeutic products after antibiotic therapy for bacterial vaginosis: study protocol for VIBRANT (vaginal lIve biotherapeutic RANdomized trial)Contemporary Clinical Trials Communications, 2025
- Effect of the vaginal live biotherapeutic LACTIN-V (Lactobacillus crispatus CTV-05) on vaginal microbiota and genital tract inflammation among women at high risk of HIV acquisition in South Africa: a phase 2, randomised, placebo-controlled trialThe Lancet Microbe, 2025
- Lactobacillus-Deficient Cervicovaginal Bacterial Communities Are Associated with Increased HIV Acquisition in Young South African WomenImmunity, 2017
- Severity of bacterial vaginosis and the risk of sexually transmitted infectionAmerican Journal of Obstetrics and Gynecology, 2011
- Bacteria in the transfer catheter tip influence the live-birth rate after in vitro fertilizationFertility and Sterility, 2000
- Bacterial vaginosis and past chlamydial infection are strongly and independently associated with tubal infertility but do not affect in vitro fertilization success ratesFertility and Sterility, 1999
- Gram stain method shows better sensitivity than clinical criteria for detection of bacterial vaginosis in surveillance of pregnant, low-income women in a clinical settingInfectious Diseases in Obstetrics and Gynecology, 1998
- Validity of the Vaginal Gram Stain for the Diagnosis of Bacterial VaginosisObstetrics & Gynecology, 1996
- Nonspecific vaginitisThe American Journal of Medicine, 1983